Please login to the form below

Not currently logged in


This page shows the latest Janssen news and features for those working in and with pharma, biotech and healthcare.

GSK’s myeloma drug hits target, prompting rapid filing pledge

GSK’s myeloma drug hits target, prompting rapid filing pledge

an anti-CD38 antibody, Janssen’s Darzalex.

Latest news

More from news
Approximately 125 fully matching, plus 348 partially matching documents found.

Latest Intelligence

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    Katrin Haeverans, EPAD LCS and POC platform support, Janssen said: “EPAD has been built to facilitate proof-of-concept trials. ... Sir Simon Lovestone. After 18 years in old age psychiatry and dementia research in academia, Sir Simon Lovestone joined

  • Deal Watch October 2018

    Product / Technology. Deal Type. Headline. ($). Arrowhead/. Janssen (J&J). Development &commercialisation of ARO‐HBV, based on.

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    The firm also has what it hopes is a best- in-class BTK inhibitor, zanubrutinib, in phase III trials, which it believes can be shown superior to Janssen’s Imbruvica.

  • The race for a HIV ‘cure’ The race for a HIV ‘cure’

    Gilead’s HIV work continues apace as does that of rivals GSK, Sanofi, Janssen and others in a global HIV drug market expected to reach a value of $26, 458bn in

  • A quest for innovative solutions A quest for innovative solutions

    Janssen adds: “We spend a lot of time asking how we, as an organisation, can prepare for this future because it is happening right now. ... There are some really exciting projects out there and we are also partnering with academic institutions to use

More from intelligence
Approximately 5 fully matching, plus 46 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 24 partially matching documents found.

Latest from PMHub

  • Attigo (part of the Mednet Group)

    Clinigen. Crohns and Colitis Department for International Development. Eisai. Gilead. Janssen.

  • Janssen & Research Partnership win prestigious BHBIA Best Business Impact award

    We are delighted to announce that Janssen and Research Partnership have won the BOBI (Best of Business Intelligence) Award in the Best Business Impact category at the BHBIA annual conference in

  • Adelphi Research UK wins Agency of the Year at BHBIA Conference

    Adelphi, Janssen and Rethink Mental Illness pro-bono work wins BHBIA Best Conference Paper. ... Adelphi were already excited to work with Janssen and Rethink to generate findings around the Mental Health Act to help lobby government changes, but to have

  • No Voice, No Choice

    The research was commissioned by Rethink Mental Illness and undertaken by Adelphi Research UK, with support from Janssen Cilag Ltd. ... Rachel Medcalf, Managing Director, Adelphi Research UK commented:. “It’s great to be involved in this crucial

  • Synergy Vision

    Amgen. Daiichi Sankyo. GlaxoSmithKline. Janssen Cilag. LEO Pharma. The Menarini Group.

More from PMHub
Approximately 5 fully matching, plus 28 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....